newsfilter
← Latest News
GlobeNewswire·

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

  • Century Therapeutics (NASDAQ: IPSC) announced its abstracts have been accepted for oral presentations at the 62nd EASD Annual Meeting in Milan (September 28–October 2, 2026) & the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia (October 9–11, 2026).
  • Both presentations will focus on CNTY-813, the company's iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0 for type 1 diabetes patients.
  • At EASD 2026, Grant Welstead, PhD, will present "CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC-Derived Islets for Off-the-Shelf Cell Therapies" on October 2, 2026.
  • At CRC 2026, Leonardo Velazco-Cruz, PhD, will present "CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC Beta Islets for Off-the-Shelf Cell Therapies" on October 9, 2026.
  • CNTY-813 utilizes proprietary immune evasion technology designed to enable durable engraftment without chronic systemic immunosuppression.
  • Preclinical data for CNTY-813 demonstrated robust glucose-responsive function, a favorable safety profile, scalable manufacturing, & immune protection under alloimmune pressure.
  • Century Therapeutics targets an IND submission for CNTY-813 in the fourth quarter of 2026.
  • Presentation details will be made available on Century Therapeutics' website following the sessions.